Keeler Thomas Management LLC acquired a new position in shares of AbbVie Inc. (NYSE:ABBV) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 6,488 shares of the company’s stock, valued at approximately $627,000.
Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Los Angeles Capital Management & Equity Research Inc. lifted its position in shares of AbbVie by 24.5% during the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 740,392 shares of the company’s stock valued at $53,686,000 after buying an additional 145,691 shares in the last quarter. Spectrum Management Group Inc. lifted its position in shares of AbbVie by 11.5% during the 2nd quarter. Spectrum Management Group Inc. now owns 28,100 shares of the company’s stock valued at $2,038,000 after buying an additional 2,892 shares in the last quarter. AGF Investments America Inc. lifted its position in shares of AbbVie by 3.6% during the 2nd quarter. AGF Investments America Inc. now owns 29,064 shares of the company’s stock valued at $2,107,000 after buying an additional 1,017 shares in the last quarter. Ffcm LLC lifted its position in shares of AbbVie by 167.2% during the 2nd quarter. Ffcm LLC now owns 1,539 shares of the company’s stock valued at $111,000 after buying an additional 963 shares in the last quarter. Finally, Fiduciary Trust Co. lifted its position in shares of AbbVie by 3.2% during the 2nd quarter. Fiduciary Trust Co. now owns 321,953 shares of the company’s stock valued at $23,345,000 after buying an additional 10,113 shares in the last quarter. 70.57% of the stock is currently owned by institutional investors and hedge funds.
In other AbbVie news, CFO William J. Chase sold 70,928 shares of the firm’s stock in a transaction on Thursday, March 1st. The stock was sold at an average price of $117.18, for a total value of $8,311,343.04. Following the completion of the sale, the chief financial officer now directly owns 203,391 shares of the company’s stock, valued at approximately $23,833,357.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Robert A. Michael sold 992 shares of the firm’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $120.31, for a total value of $119,347.52. The disclosure for this sale can be found here. Insiders sold a total of 211,197 shares of company stock valued at $24,585,575 over the last ninety days. Corporate insiders own 0.07% of the company’s stock.
A number of research analysts have recently issued reports on ABBV shares. BMO Capital Markets decreased their target price on AbbVie from $95.00 to $80.00 and set an “underperform” rating on the stock in a research report on Friday, March 23rd. Jefferies Group set a $125.00 price objective on AbbVie and gave the company a “buy” rating in a report on Friday, March 23rd. Credit Suisse Group decreased their price objective on AbbVie from $109.00 to $98.10 and set a “neutral” rating on the stock in a report on Friday, March 23rd. Bank of America set a $120.00 price objective on AbbVie and gave the company a “hold” rating in a report on Monday, March 26th. Finally, Zacks Investment Research upgraded AbbVie from a “hold” rating to a “buy” rating and set a $115.00 price objective on the stock in a report on Thursday, January 18th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $117.85.
Shares of ABBV opened at $94.32 on Thursday. AbbVie Inc. has a 52-week low of $63.29 and a 52-week high of $125.86. The firm has a market capitalization of $147,046.30, a price-to-earnings ratio of 16.84, a P/E/G ratio of 0.89 and a beta of 1.61. The company has a debt-to-equity ratio of 6.07, a current ratio of 1.28 and a quick ratio of 1.18.
AbbVie (NYSE:ABBV) last issued its earnings results on Friday, January 26th. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.44 by $0.04. AbbVie had a return on equity of 158.15% and a net margin of 18.82%. The business had revenue of $7.74 billion during the quarter, compared to the consensus estimate of $7.53 billion. During the same period last year, the company earned $1.20 EPS. The company’s revenue for the quarter was up 13.9% on a year-over-year basis. sell-side analysts forecast that AbbVie Inc. will post 7.53 EPS for the current fiscal year.
AbbVie announced that its Board of Directors has initiated a share repurchase program on Thursday, February 15th that authorizes the company to repurchase $10.00 billion in shares. This repurchase authorization authorizes the company to repurchase shares of its stock through open market purchases. Shares repurchase programs are generally a sign that the company’s leadership believes its shares are undervalued.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, May 15th. Shareholders of record on Friday, April 13th will be paid a $0.96 dividend. The ex-dividend date of this dividend is Thursday, April 12th. This is an increase from AbbVie’s previous quarterly dividend of $0.71. This represents a $3.84 dividend on an annualized basis and a dividend yield of 4.07%. AbbVie’s dividend payout ratio (DPR) is 68.57%.
TRADEMARK VIOLATION WARNING: “Keeler Thomas Management LLC Invests $627,000 in AbbVie Inc. (ABBV)” was published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://www.thelincolnianonline.com/2018/04/19/keeler-thomas-management-llc-invests-627000-in-abbvie-inc-abbv.html.
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C.
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.